Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients



Status:Active, not recruiting
Conditions:High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:5 - 21
Updated:5/30/2018
Start Date:November 2009
End Date:December 2018

Use our guide to learn which trials are right for you!

Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients

The proposed study will investigate the effect of chronotherapeutic alteration of
anti-hypertensive medication on nocturnal hypertension and end-organ injury in pediatric
renal transplant recipients who are non-dippers. Additionally, the investigators aim to
examine the association between response to intervention, serum adiponectin levels and
adiponectin gene polymorphisms. The investigators hypothesize that (1) evening administration
of anti-hypertensive medication will convert subjects from non-dipper to dipper status,
improve mean nocturnal blood pressure (BP), and improve nocturnal BP load, (2) evening
administration of anti-hypertensive medication will reduce albuminuria, left ventricular mass
index (LVMI), rate of decline of glomerular filtration rate (eGFR) and will decrease pulse
wave velocity (PWV), and (3) lower adiponectin levels and presence of adiponectin gene
polymorphisms will be associated with less of a response to the intervention.


Inclusion Criteria:

- Subjects age 5-21 years

- Stable kidney transplant recipients (<30% change in eGFR in past 3 months)

- eGFR > 30 ml/min/1.73 m2

- >6 months since kidney transplant

- ABPM: Non-dipper status defined as <10% decline in systolic or diastolic blood
pressure from daytime to night-time

Exclusion Criteria:

- ABPM: Subjects with daytime mean blood pressure > 95% for height and sex

- Subjects on diuretic monotherapy will not be eligible for the time change group (to
avoid discomfort of nocturnal enuresis)

- Subjects with nephrotic range proteinuria

- Subjects with major co-morbid conditions such as cardiac disease, pulmonary disease
and diabetes mellitus

- Subjects/guardians or subjects who, in the opinion of the Investigator, may be
non-compliant with study schedules or procedures

- Subjects who are pregnant will not be eligible for the new medication group
We found this trial at
2
sites
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Kevin EC Meyers, MbbCh
Phone: 215-590-2449
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
New Hyde Park, New York 11040
Principal Investigator: Christine B Sethna, MD, EdM
Phone: 718-470-3423
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials